These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32391948)

  • 21. Survival of Patients With Short-Bowel Syndrome on Home Parenteral Nutrition: A Prospective Cohort Study.
    Noelting J; Gramlich L; Whittaker S; Armstrong D; Marliss E; Jurewitsch B; Raman M; Duerksen DR; Stevenson D; Lou W; Saha S; Allard JP
    JPEN J Parenter Enteral Nutr; 2021 Jul; 45(5):1083-1088. PubMed ID: 32740954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.
    Hill S; Carter BA; Cohran V; Horslen S; Kaufman SS; Kocoshis SA; Mercer DF; Merritt RJ; Pakarinen MP; Protheroe S; Thompson JF; Vanderpool CPB; Venick RS; Wales PW; Smith SE; Yoon M; Grimm AA
    JPEN J Parenter Enteral Nutr; 2021 Sep; 45(7):1456-1465. PubMed ID: 33305440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report.
    Pevny S; Pape UF; Elezkurtaj S; Rieger A; Jürgensen C; Blüthner E; Jochum C; Tacke F; Maasberg S
    JPEN J Parenter Enteral Nutr; 2021 Mar; 45(3):652-656. PubMed ID: 32740933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.
    Norona J; Apostolova P; Schmidt D; Ihlemann R; Reischmann N; Taylor G; Köhler N; de Heer J; Heeg S; Andrieux G; Siranosian BA; Schmitt-Graeff A; Pfeifer D; Catalano A; Frew IJ; Proietti M; Grimbacher B; Bulashevska A; Bhatt AS; Brummer T; Clauditz T; Zabelina T; Kroeger N; Blazar BR; Boerries M; Ayuk F; Zeiser R
    Blood; 2020 Sep; 136(12):1442-1455. PubMed ID: 32542357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.
    Hinchliffe T; Pauline ML; Wizzard PR; Nation PN; Brubaker P; Campbell JR; Kim Y; Dimitriadou V; Wales PW; Turner JM
    JPEN J Parenter Enteral Nutr; 2021 Sep; 45(7):1466-1474. PubMed ID: 33241564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data.
    Ramos Boluda E; Redecillas Ferreiro S; Manrique Moral O; García Romero R; Irastorza Terradillos I; Nuñez Ramos R; Germán Díaz M; Polo Miquel B; Vives Piñera I; Alcolea Sánchez A; González Sacristán R; Bautista Barea M; Moreno Villares JM
    J Pediatr Gastroenterol Nutr; 2020 Dec; 71(6):734-739. PubMed ID: 32804906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure.
    Martin A; Boehm V; Zappa M; Billiauws L; Bonvalet F; Nuzzo A; Vilgrain V; Joly F; Ronot M
    Am J Clin Nutr; 2021 May; 113(5):1343-1350. PubMed ID: 33675349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?
    Solar H; Doeyo M; Ortega M; De Barrio S; Olano E; Moreira E; Buncuga M; Manzur A; Crivelli A; Gondolesi G
    JPEN J Parenter Enteral Nutr; 2021 Jul; 45(5):1072-1082. PubMed ID: 32740966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teduglutide for pediatric short bowel syndrome patients.
    Rosete BE; Wendel D; Horslen SP
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):727-733. PubMed ID: 33798402
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparing the Intestinotrophic Effects of 2 Glucagon-Like Peptide-2 Analogues in the Treatment of Short-Bowel Syndrome in Neonatal Piglets.
    Pauline ML; Nation PN; Wizzard PR; Hinchliffe T; Wu T; Dimitriadou V; Turner JM; Wales PW
    JPEN J Parenter Enteral Nutr; 2021 Mar; 45(3):538-545. PubMed ID: 32437048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of American teduglutide consumers from 2015 to 2020: A large database study.
    Loutfy A; Kurin M; Shah R; Davitkov P
    JPEN J Parenter Enteral Nutr; 2022 Mar; 46(3):646-651. PubMed ID: 34291485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.
    Chen K; Joly F; Mu F; Kelkar SS; Olivier C; Xie J; Seidner DL
    Clin Nutr ESPEN; 2021 Jun; 43():420-427. PubMed ID: 34024550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn's Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared.
    Borghini R; Villanacci V; Oberti A; Caronna R; Trecca A
    Inflamm Bowel Dis; 2021 Nov; 27(12):e152-e153. PubMed ID: 34255043
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
    Raghu VK; Rudolph JA; Smith KJ
    Am J Clin Nutr; 2021 Jan; 113(1):172-178. PubMed ID: 33021637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Is there life after teduglutide?].
    Martínez Martínez AL; Calles Romero LA; Etxeberría Martín E; Monasterio Jiménez O; Zabalegui Eguinoa A; Paja Fano M; Monzón Mendiolea A; Cadenas González A; Cabriada Nuno JL; Iglesias Hernández NC
    Nutr Hosp; 2020 Jul; 34(3):631-635. PubMed ID: 32406744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression, purification and molecular dynamics simulation of extracellular domain of glucagon-like peptide-2 receptor linked to teduglutide.
    Jamshidi Kandjani O; Alizadeh AA; Moosavi-Movahedi AA; Dastmalchi S
    Int J Biol Macromol; 2021 Aug; 184():812-820. PubMed ID: 34174312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide 2 analogues in the treatment of intestinal failure: A qualitative exploration of the views of patients and their families in decision making.
    Sowerbutts AM; Burden S; Griffiths J; Abraham A; Farrer K; Leahy G; Teubner A; Cloutier A; Twist K; Kelly S; Lal S
    Clin Nutr ESPEN; 2021 Aug; 44():263-269. PubMed ID: 34330477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety of available treatment options for short bowel syndrome and unmet needs.
    Pironi L; Raschi E; Sasdelli AS
    Expert Opin Drug Saf; 2021 Dec; 20(12):1501-1513. PubMed ID: 34105428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome.
    Marier JF; Jomphe C; Peyret T; Wang Y
    Clin Transl Sci; 2021 Nov; 14(6):2497-2509. PubMed ID: 34402197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Candidacy of adult patients with short bowel syndrome for treatment with glucagon-like peptide-2 analogues: A systematic analysis of a single centre cohort.
    Pironi L; Sasdelli AS; Venerito FM; Musio A; Pazzeschi C; Guidetti M
    Clin Nutr; 2021 Jun; 40(6):4065-4074. PubMed ID: 33637328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.